Initial meeting of Scientific Advisory Board (SAB) convened to discuss the first-in-human phase 1a/1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies.
Read moreNews
There is always something new at ImmunoGenesis. Stay on top of the latest.
Press Releases
ImmunoGenesis to Present IMGS-001 Phase 1a/1b Clinical Study Updates at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
IMGS-001 is first dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function and is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies.
Read more
ImmunoGenesis Expands Phase 1a/b Trial of IMGS-001 for Advanced Solid Tumors to Ochsner MD Anderson Cancer Center
First dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies. Promising early signals of activity seen as Phase 1 dose escalation proceeds.
Read moreKey Publications
Abstract TPS2686: A phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of IMGS-001 in patients with relapsed or refractory advanced solid tumors.
D Hong, S Sen, C Schweizer, A Sanders, C Grimes, F Pericle, C Gagliardi, J Barlow, A Salameh, M Curran. Poster presented at: American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2025; Chicago, IL.
A potent STING agonist induces endothelial PD-L1 and enhances antitumor efficacy of a novel PD-L1/PD-L2 antibody.
A Salameh, C Gagliardi, L Conti, E Bolli, C Cossu, M Ceci, M Iezzi, F Cavallo, J Barlow, F Pericle. Poster presented at: American Association for Cancer Research Annual Meeting; April 25-30, 2025; Chicago, IL.
Development of IMGS-001, a novel anti–PD-L1/PD-L2 dual-specific, multifunctional antibody, to treat immune-excluded tumors.
C Gagliardi, A Salameh, P Blezinger, M Hemberger, C Schweizer, J Barlow, M Curran, F Pericle. Poster presented at: Society for Immunotherapy of Cancer Annual Meeting; November 8-12, 2022; Boston, MA.
Preclinical characterization of IMGS-001, a dual-antagonist anti–PD-L1 and PD-L2 antibody with effector function, to treat patients resistant to immune checkpoint blockade.
A Salameh, C Gagliardi, P Blezinger, M Hemberger, C Schweizer, J Barlow, M Curran, F Pericle. Poster presented at: Society for Immunotherapy of Cancer Annual Meeting; November 8-12, 2022; Boston, MA.
Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
Burrack, AL, Spartz, EJ, Raynor, JF, Wang, I, Olson, M, Stromnes, IM. Cell Reports. 2019.
Genomic biomarkers in relation to PD-1 checkpoint blockade response.
Seiwert, TY, Cristescu, R, Kaufman, DR, et al. Journal of Clinical Oncology. 2018.
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Yearley, JH, Gibson, C, Yu, N, Moon, C, Murphy, E, McClanahan, T, et al. Clinical Cancer Research. 2017.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Curran, MA, Montalvo, W, Yagita, H, Allison, JP. PNAS. 2010.
Upcoming events
There are no upcoming events scheduled at this time. Sign up to receive notices about upcoming events and press releases.
Excited about what you see?
Learn more